---
title: "Guizhou Bailing Group Pharmaceutical Co., Ltd. (002424.SZ)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/002424.SZ.md"
symbol: "002424.SZ"
name: "Guizhou Bailing Group Pharmaceutical Co., Ltd."
industry: "Pharmaceuticals"
---

# Guizhou Bailing Group Pharmaceutical Co., Ltd. (002424.SZ)

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Location | CN Market |
| Website | [www.gzbl.com](https://www.gzbl.com) |

## Company Profile

Guizhou Bailing Group Pharmaceutical Co., Ltd., together with its subsidiaries, researches, develops, produces, and sells medicines in China. It operates through four segments: Industrial, Commerce, Medical institutions, and Others The company offers medicines in various forms, including tablets, ca...

## Financial Score

> *Longbridge Financial Score™ — Proprietary multi-factor rating model by [Longbridge](https://longbridge.com). This score is independently calculated by Longbridge and is not affiliated with any third-party rating agency.*
> Updated: 2026-02-20T04:30:09.000Z

**Overall: C (0.54)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 128 / 222 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

### Score Analysis

**Style Score**: 

#### Growth Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -25.47% |  |
| Net Profit YoY | 100.48% |  |

#### Value Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| P/B Ratio | 1.87 |  |
| Dividend Ratio | 0.00% |  |


**Size Score**: 

#### Market Cap Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 6.09B |  |

#### Revenue Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue | 3.15B |  |


**Multi Score**: C

#### Profit Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 0.07% | D |
| Profit Margin | 0.07% | D |
| Gross Margin | 58.34% | B |

#### Growth Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -25.47% | E |
| Net Profit YoY | 100.48% | A |
| Total Assets YoY | -12.13% | E |
| Net Assets YoY | -6.07% | D |

#### Cash Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| Cash Flow Margin | 141940.39% | A |
| OCF YoY | -25.47% | E |

#### Operating Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| Turnover | 0.47 | C |

#### Debt Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| Gearing Ratio | 47.78% | C |


```chart-data:radar
{
  "title": "Longbridge Financial Score - Guizhou Bailing Group Pharmaceutical Co., Ltd.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Profit",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "0.07%",
          "rating": "D"
        },
        {
          "name": "Profit Margin",
          "value": "0.07%",
          "rating": "D"
        },
        {
          "name": "Gross Margin",
          "value": "58.34%",
          "rating": "B"
        }
      ]
    },
    {
      "name": "Growth",
      "grade": "D",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-25.47%",
          "rating": "E"
        },
        {
          "name": "Net Profit YoY",
          "value": "100.48%",
          "rating": "A"
        },
        {
          "name": "Total Assets YoY",
          "value": "-12.13%",
          "rating": "E"
        },
        {
          "name": "Net Assets YoY",
          "value": "-6.07%",
          "rating": "D"
        }
      ]
    },
    {
      "name": "Cash",
      "grade": "C",
      "indicators": [
        {
          "name": "Cash Flow Margin",
          "value": "141940.39%",
          "rating": "A"
        },
        {
          "name": "OCF YoY",
          "value": "-25.47%",
          "rating": "E"
        }
      ]
    },
    {
      "name": "Operating",
      "grade": "C",
      "indicators": [
        {
          "name": "Turnover",
          "value": "0.47",
          "rating": "C"
        }
      ]
    },
    {
      "name": "Security",
      "grade": "C",
      "indicators": [
        {
          "name": "Gearing Ratio",
          "value": "47.78%",
          "rating": "C"
        }
      ]
    }
  ]
}
```

### Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
|------|------|--------|--------|-----------|----------|------|--------|
| 01 | Allist (SH.688578) | A | A | B | A | B | A |
| 02 | Xingqi Pharmaceutical (SZ.300573) | A | A | A | B | B | A |
| 03 | Hengrui Pharma (SH.600276) | A | B | C | A | B | B |
| 04 | Yunnan Baiyao (SZ.000538) | B | C | B | B | C | B |
| 05 | Salubris (SZ.002294) | B | B | C | A | B | B |

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 2744.42 | 162/222 | 3462.00 | 2599.65 | 969.70 |
| PB | 1.87 | 65/222 | 2.51 | 2.18 | 1.74 |
| PS (TTM) | 1.93 | 32/222 | 2.58 | 2.20 | 1.69 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2023-08-24T16:00:00.000Z

Total Analysts: **1**

| Rating | Count | Percentage |
|--------|-------|-----------|
| Buy | 1 | 100% |
| Overweight | 0 | 0% |
| Hold | 0 | 0% |
| Underweight | 0 | 0% |
| Sell | 0 | 0% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 4.36 |

## References

- [Company Overview](https://longbridge.com/en/quote/002424.SZ/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/002424.SZ/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/002424.SZ/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.
